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Abstract
Chinese medicine has been used to treat a variety of cancer-related conditions. This study aims to examine the
prevalence and patterns of Chinese medicine usage by cancer patients. We reviewed articles written in English and
found only the Chinese medicine usage from the studies on complementary and alternative medicine (CAM).
Seventy four (74) out of 81 articles reported rates of CAM usage ranging from 2.6 to 100%. Acupuncture was
reported in 71 out of 81 studies. Other less commonly reported modalities included Qigong (n = 17), Chinese
herbal medicine (n = 11), Taichi (n = 10), acupressure (n = 6), moxibustion (n = 2), Chinese dietary therapy (n = 1),
Chinese massage (n = 1), cupping (n = 1) and other Chinese medicine modalities (n = 19). This review also found
important limitations of the English language articles on CAM usage in cancer patients. Our results show that
Chinese medicine, in particular Chinese herbal medicine, is commonly used by cancer patients. Further research is
warranted to include studies not written in English.
Background
Conventional cancer treatments such as chemotherapy
and radiation therapy have shown some effectiveness for
reducing or eradicating cancers; however, they can pro-
duce unpleasant side effects, e.g. nausea, vomiting,
changes in bowel habits, fatigue and hair loss. Chinese
medicine is increasingly used as an adjunctive treatment
option for cancer patients and a way of reducing or
managing side effects of conventional cancer treatment.
Chinese medicinal herbs such as Ginkgo biloba has
been reported to have chemo-preventive activities for
treating certain cancers such as ovarian, breast and
brain [1]. Acupuncture is being used to relieve side
effects of conventional cancer treatment. While some
laboratory and clinical research found some immune
boosting capabilities of acupuncture in cancer patients
[2,3], most clinical research has focused on symptom
management, in particular, the management of che-
motherapy induced nausea and vomiting [4-6].
This study reviews the articles published in English lan-
guage complementary and alternative medicine (CAM)
literature on the prevalence and patterns of Chinese
medicine usage by cancer patients and informs patients,
researchers, health care providers and policy makers of
the current use of Chinese medicine in the CAM context.
Methods
Literature search
Our working definition of CAM was an inclusive term
incorporating both complementary medicine and thera-
pies (modalities and/or systems), namely the concepts of
health and medical systems, practices and products not
currently recognised as part of conventional medicine,
alternative medicine, traditional medicine (indigenous
medicine and practices), and integrative medicine (CAM
used alongside with the mainstream medicine) [7]. For
the purposes of this review Chinese medicine includes
acupuncture, Chinese herbal medicine, remedial mas-
sage, exercise and breathing therapy (e.g. Qigong) as well
as diet and lifestyle advice in primary health care [8].
We searched major databases, namely AMED,
CINAHL, PubMED, Science Direct and Cochrane
Library, using specific terms to retrieve surveys pub-
lished in English. One author (BC) screened all the titles
and abstracts to identify relevant studies. Survey studies
containing prevalence rates for at least one Chinese
medicine modality for treating cancer patients were
included. Studies on children were not excluded.
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The following data was extracted: country of study,
number of study participants, type of study (quantitative,
qualitative, mixed), group setting (e.g. hospital, cancer
registry), type of cancer, age, gender, ethnicity, marital
status, education, prevalence of individual Chinese medi-
cine modality, prevalence, sources of CAM information
and reasons for CAM usage.
Quality-assessment
The quality of the CAM surveys were assessed accord-
ing to Bishop et al. [9], based on the Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) statement [10]. Reported information was
assessed with scores which were weighted for impor-
tance. Both authors (BC and CAS) scored the included
articles. Final scores were consensus of both authors.
Four articles [11-14] were primarily qualitative and
therefore not assessed. Three items were scored a maxi-
mum of two points, eight items one point and six items
0.5 points. The maximum total score was 17.
Data analysis
We described the general characteristics of users of Chi-
nese medicine including both Chinese medicine specific
studies and Chinese medicine embedded within CAM
studies. Data was analysed with SPSS Statistics 17.0
(IBM, USA). Descriptive statistics, means, medians,
ranges, frequencies and percentages characterised the
studies.
Results
The search identified a total of 411 studies for screen-
ing. Ninety nine screened articles were retrieved for
further evaluation. Eighty one studies met the inclusion
criteria and were included in this review (Figure 1).
Characteristics of the studies
The included 81 studies spanned a period of 15 years
(Table 1), with the majority published in the last five
years (60.5%). While the surveys were carried out around
the world, a large number of surveys were conducted in
North America, the United States (US) in particular
(33.3%). Sample sizes of the studies ranged from 16 to
22,352 with a median of 189 participants. Two thirds of
the participants were female (66.7%). Participants had a
mean age of 56.0 ± 11.9 years (mean ± standard devia-
tion, SD) (ranging from 3 to 71 years), were married or in
a de facto marriage (70.6%) and had completed high
school education (35.8%). The majority (84.5%) were of
Caucasian ethnicity. Survey participants were recruited
from hospital settings including outpatient clinics, cancer
institutes and palliative care (70.4%), with convenience
sampling (61%). Participants had a range of cancers
(49.4%); however, a significant focus was on women with
breast cancer (25.9%). Most studies used a self-adminis-
tered questionnaire (52%).
Prevalence of Chinese medicine use
Seventy four studies reported the rates of CAM usage
which ranged from 2.6 to 100%. Acupuncture was the
most frequently reported Chinese medicine modality
included within CAM. A total of 71 studies reported
data on acupuncture. Other less commonly reported
modalities included Qigong, Chinese herbal medicine,
Taichi, acupressure, moxibustion, Chinese dietary ther-
apy, Chinese massage and cupping.
We examined the prevalence of Chinese medicine usage
and reported the range and a mean prevalence (Table 2).
Chinese herbal medicine was the most frequently used
modality within Chinese medicine; however data were
only available from 11 of the 81 studies. Usage ranged
from a low prevalence of 0.7% to a high prevalence of
94.4%, with an average use rate of 35.6%. Acupuncture
prevalence ranged from 0.2 to 17.1% with a mean of 4.5%
extracted from 71 studies. Usage of Qigong by cancer
patients was reported in 17 studies with a mean prevalence
rate of 12.7%. Usage reported in these studies ranged from
0.4 to 100%. Taichi prevalence ranged from 1.7 to 40.6%
reported in ten studies with a mean of 9.0%. Other Chi-
nese medicine modalities (acupressure, Chinese dietary
therapies, Chinese massage, moxibustion and cupping)
411 potentially relevant 
studies screened
131 abstracts
280 excluded – irrelevant eg
animal pharmacological 
studies
99 studies (full text retrieved) 
for review
32 excluded  (editorials, 
mixed groups eg cancer & 
chronic pain)
81 articles included
18 excluded (qualitative 
studies, lack of CM data)
Figure 1 Process of study identification and selection.
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Number of studies %
Year (in 5-year blocks)
2010 7 8.6
2009-2005 49 60.5
2004-2000 22 27.2
1999-1995 3 3.7
Country (by region)
North America 35 43.2
UK & Europe 20 24.7
Asia 19 23.5
Middle East 3 3.7
Australia and New Zealand 3 3.7
Multiple 1 1.2
Country or region (by individual countries or regions)
US 27 33.3
Canada 8 9.9
UK 7 8.6
Europe 6 7.4
Taiwan 4 4.9
Other individual countries 29 35.9
Group setting
Hospital including outpatient clinics, cancer institutes, palliative care 57 70.4
Cancer/tumour registry 12 14.8
General Population 6 7.4
Other 6 7.4
Data Collection Methods
Self-report questionnaire 42 51.9
Interviewer led (in person or telephone) 37 45.7
Database e.g. insurance claims 2 2.5
Sampling method
Random 18 22.2
Systematic 6 7.4
Stratified 7 8.6
Convenience 50 61.7
Cancer type
Various (mixed cancers within groups) 40 49.4
Breast 21 25.9
Prostate 5 6.2
Other 15 18.5
Gender, mean %
Female 66.7
Male 33.2
Age, mean (Missing data = 31) 56.0
Marital status, mean % (Missing data = 34)
Married or de-facto 70.6
Other 29.4
Education, mean % (Missing data = 27)
Primary School 12.3
High School 35.8
University 18.5
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these modalities (Table 2). Mixed Chinese medicine preva-
lence rates (where cancer patients reported using several
Chinese modalities concurrently) were also reported.
Nineteen of the studies reported such data with a mean
prevalence of 17.8% (ranging from 0.3 to 100%).
Use patterns of Chinese medicine modalities
Our search identified nine studies that provided detailed
data on the usage patterns of Chinese medicine
[11,15-22]. The aims of these studies were quite diverse.
We were not able to provide a systematic summary of
these data but a narrative summary.
Studies examining patterns of Chinese medicine usage
varied in study design. One study used qualitative meth-
ods [11]; another study used a retrospective analysis of
insurance registration and claim datasets [20], and seven
studies were questionnaire-based surveys [15-19,21,22].
All seven surveys included Chinese or other Asian
populations (Mainland China, Taiwan, Hong Kong, Sin-
gapore), or Chinese immigrants in Canada. Seven stu-
dies reported an overall Chinese medicine usage rate
attributed to Chinese medicinal herbs, Qigong, acupunc-
ture and moxibustion.
Within the nine studies, usage of Chinese medicinal
herbs varied widely; however the majority reported high
usage of 94.4% [19], 93.75% [11], 86.4% [17], 76.75%
[15] and one low rate of 2.48% [20]. Examples are pre-
sented in the following studies. Shih et al. [22] reported
additional details on the types of Chinese medicinal
herbs and related modalities in particular food supple-
ments. Forty five percent of participants used bird (swal-
low) nests and 28.6% chicken essence; 53% used
prescribed herbs, of which 15.4% used Lingzhi, and 8%
used Chinese herbal formulae. In the study by Xu et al.
[11], 50% of participants used individually tailored
herbs, 6% standard herbal formulae and 38% both types.
Xu et al. reported that all participants (n = 16) practiced
Qigong.
Characteristics of Chinese medicine users
Three [17,18,21] of the nine studies reported the charac-
teristics of Chinese medicine users. Pu et al. [21] sur-
veyed 2034 patients with cervical, breast, lung, liver and
colorectal cancers and highlighted patients’ usage of
Chinese medicine modalities according to cancer types.
Chinese medicine as a broad modality was more likely
to be used by patients with breast, lung, liver and color-
ectal cancers whereas acupuncture was more likely to be
used by liver and colorectal patients. Pu et al.e x a m i n e d
the correlation of socio-economic factors (e.g. religion,
education and income) with Chinese medicine usage.
While more Buddhists used Chinese medicine, acupunc-
ture usage was not distinctive in patients with any reli-
gion. Acupuncture users were mostly female cancer
patients with higher education. According to the study
by Pu et al., participants earning a higher income were
about 52% more likely than lower income groups to use
Chinese medicine. Similarly, Cui et al. [17] found that
more participants with a higher education and higher
income used Chinese herbal medicine. Ferro et al. [18]
found that Chinese medicine was used by less accultu-
rated patients twice as much as acculturated patients.
Motivation to use and the perceived effectiveness of
Chinese medicine
Motivation to use and the perceived effectiveness of
Chinese medicine modalities were reported in three stu-
dies [11,15,17]. Xu et al. [11] highlighted four important
reasons for Chinese medicine usage among 28 Chinese
cancer patients: (1) Chinese medicine as a popular and
culturally acceptable process of self-help, (2) fear of che-
motherapy damaging the vital essence, (3) importance of
individualised prescriptions and (4) empowerment with
self-help. Almost all participants used Chinese medicine
to avoid or reduce adverse effects from cancer treat-
ment. Overall, health benefits, quality of life and ability
to function were significantly improved with Chinese
medicine. Benefits attributed to Chinese medicine
Table 2 Prevalence of CAM and Chinese Medicine usage
Modality (No. of studies) Prevalence Mean % SD Prevalence Min % Prevalence Max %
CAM (74) 49.3 24.5 2.6 100
Chinese herbal medicine (11) 35.6 42.1 0.7 94.4
Mixed Chinese medicine (19) 17.8 28.6 0.3 100
Chinese dietary therapy (1) 16.7 - 16.7 16.7
Qigong (17) 12.7 25.2 0.4 100
Taichi (10) 9.0 11.5 1.7 40.6
Acupressure (6) 6.3 6.4 1.1 18.8
Acupuncture (71) 4.5 3.8 0.2 17.1
Moxibustion (2) 2.4 1.1 1.7 3.2
Chinese massage (1) 2.4 - 2.4 2.4
Cupping (1) 1.3 - 1.3 1.3
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tion, stress, weakness and weight gain.
Cui et al. [17] found that the most common reason
for using Chinese herbal medicine among breast cancer
patients was cancer treatment (81.5%), followed by
immune system enhancement (12%), metastasis preven-
tion or side effect management (7.9%), and the reduc-
tion of menopausal symptoms (4.7%). Chinese herbal
medicine was perceived to be effective or very effective
for cancer treatment (78.7%), and 77% of female patients
perceived Chinese medicine to be very effective or effec-
tive for immune system enhancement. Similar levels of
effectiveness were reported for metastasis management
and the reduction of menopausal symptoms. Acupunc-
ture, on the other hand, was reported to be less effective
with only 48.1% of users considering it to be effective.
Chen et al. [15] found far more sceptical views among
breast cancer patients with only 52% of patients perceiv-
ing Chinese herbal medicine as effective and 4% as very
effective in assisting cancer treatment.
Study quality
Overal study quality (Additional file 1) was scored between
32 and 94%, with 95% of studies scoring above a 50%
threshold for the 77 quantitiave studies [15-91]. Fourty
four studies omitted piloting of instruments. Fourty seven
studies used convenience sampling. Only eight studies
reported non-response bias. Overall measures of socio-
economic status were included and reported. All studies
reported prevalence but many failed to examine the rea-
sons for usage. Many cancer studies (n = 11) reported the
usage starting from the time of diagnosis, thereby omitting
patterns of usage prior to diagnosis.
Discussion
Acupuncture was the most frequently reported Chinese
medicine modality with nearly 90% of the studies con-
taining prevalence data. However, among more compre-
hensive studies of Chinese medicine modalities, Chinese
herbal medicine was the most commonly used form of
Chinese medicine.
Increasing prevalence of CAM usage by cancer
patients reflects the growing use of CAM over time
[92]. Our review suggests a higher CAM prevalence
c o m p a r e dw i t hap r e v a l e n c eo f3 1 . 4 % ,a n dar a n g eo f
7-64%, reported by Ernst [93]. However, unlike Ernst,
we were unable to access non-English language
publications.
Major limitations of the studies on the use of Chinese
medicine in relation to cancer are as follows. Firstly, non-
English language studies, in particular those written in
Chinese, were not reviewed and should be included in
future studies. Moreover, the inability to access the
EMBASE database might have excluded some English
language reports. Secondly, the variation in the wide range
of CAM use is likely explainable by different cultural con-
texts, understandings and definitions of what constitutes
CAM. Thirdly, incomplete reporting of the definition of
CAM adopted by many studies, and the lack of rationale
for selecting Chinese medicine modalities were not
uncommon. Furthermore, extensive demographic charac-
teristics and related details were not reported. Sampling of
the participant population and the generalisability of the
findings was not justified. Fourthly, qualitative research
accompanied by cross sectional and longitudinal surveys
and additional information about cultural and ethnic
populations was insufficient for cross cultural compari-
sons. Further studies should address these limitations.
Conclusion
Our results show that Chinese medicine, in particular
Chinese herbal medicine, is commonly used by cancer
patients. Further research is warranted to include studies
not written in English.
Additional material
Additional file 1: Summary of QAT Scores (n = 77). Summary of QAT
Scores
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